February 1, 2024

Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The gene editing technology CRISPR offers potential for treating both hematologic cancer and solid tumors.

“The promise with the technology is now we can use our own immune system and use it as a targeted therapy against cancer,” says Faiz Anwer, MD, a hematologist at Cleveland Clinic who leads bone marrow transplant, stem cell transplant and CAR T-cell therapy for multiple myeloma indication.

In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Anwer provides an overview on the current state of CRISPR technology, including:

  • How the gene-editing technology works
  • Clinical studies indicating successful use of CRISPR technology
  • When CRISPR may be a preferred treatment compared to cellular therapies and stem cell transplants
  • The potential for treating genetic disorders, such as blindness, cystic fibrosis and liver conditions
  • Barriers to further development of treatments, including off-target effects and germline mutations

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Cancer Advances episodes at clevelandclinic.org/podcasts/cancer-advances or wherever you get your podcasts.


Excerpt from the podcast:

Podcast host Dale Shepard, MD, PhD: When we think about this technology, give us a little bit of a background on how it’s been utilized for treating cancer so far.

Anwer: So, this is very timely because we just initiated a phase 1 clinical trial with a pharmaceutical company. It’s a multi-institute study where we’re using a cancer-fighting T cell – and T cells are immune cells. Their main job is to fight against infections as well as cancers. And through this CRISPR technology, the allogeneic cells which came from a healthy donor were modified. Those T cells are now able to find and attack and kill cancer cells. And we are using it for the treatment of multiple myeloma.

In this particular case, this cell is modified in four different ways where they have removed a T-cell receptor and inserted a new receptor, which can find a cancer target called the BCMA protein. And on the other end, through this technology, they have modified the cell, so it does not attack the patient’s body – so it does not cause graft-versus-host disease.


And they have also modified the cell in a way that the patient’s host immune system does not attack and kill the donor cell. So, it is protected from the rejection of these cells. Through these edits, now these cells can stay in the body and potentially be very effective in eradicating cancer from the body.

Related Articles

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

23-CNR-4318382-CQD-Hero-650×450 Dr Hill
December 19, 2023
Active Surveillance may be a Feasible Option for a Subset of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Large cohort study finds no reduction in survival for patients managed with active surveillance compared to treated patients

Dr. Caimi
December 15, 2023
CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

23-CNR-4344308-CQD-Hero-650×450 Ornstein
December 14, 2023
Belzutifan Shows Improvement in Progression-Free Survival for Patients with Refractory Clear-Cell Kidney Cancer

Belzutifan superior to everolimus in phase 3 clinical trial

Relapsed refractory multiple myeloma treatment
December 12, 2023
Teclistamab Appears Safe and Effective in Real-World Patients with Relapsed/Refractory Multiple Myeloma

Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial

23-CNR-4419109-CQD-Hero-650×450 Dr Sauter
December 11, 2023
Cell Therapy Offers New Hope for Refractory/Relapsed AML

Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia